BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, Colombo M, Delarocque-Astagneau E, Dusheiko G, Esmat G, Esteban R, Goldberg D, Gore C, Lok AS, Manns M, Marcellin P, Papatheodoridis G, Peterle A, Prati D, Piorkowsky N, Rizzetto M, Roudot-Thoraval F, Soriano V, Thomas HC, Thursz M, Valla D, van Damme P, Veldhuijzen IK, Wedemeyer H, Wiessing L, Zanetti AR, Janssen HL. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat. 2011;18 Suppl 1:1-16. [PMID: 21824223 DOI: 10.1111/j.1365-2893.2011.01499.x] [Cited by in Crossref: 159] [Cited by in F6Publishing: 155] [Article Influence: 14.5] [Reference Citation Analysis]
Number Citing Articles
1 Wei L, Lok AS. Impact of new hepatitis C treatments in different regions of the world. Gastroenterology 2014; 146: 1145-50. e1-4. [PMID: 24662488 DOI: 10.1053/j.gastro.2014.03.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
2 Chen JY, Chung RT. Future classes of hepatitis C virus therapeutic agents. Infect Dis Clin North Am 2012;26:949-66. [PMID: 23083826 DOI: 10.1016/j.idc.2012.08.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Martins T, Machado DF, Schuelter-Trevisol F, Trevisol DJ, Vieira e Silva RA, Narciso-Schiavon JL, Schiavon Lde L. Prevalence and factors associated with HCV infection among elderly individuals in a southern Brazilian city. Rev Soc Bras Med Trop 2013;46:281-7. [PMID: 23856863 DOI: 10.1590/0037-8682-0026-2013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
4 Akpo EI, Cerri K, Kleintjens J. Predicting the impact of adverse events and treatment duration on medical resource utilization-related costs in hepatitis C genotype 1 treatment-naïve patients receiving antiviral therapy. Pharmacoeconomics 2015;33:409-22. [PMID: 25577042 DOI: 10.1007/s40273-014-0249-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Salvatierra K, Fareleski S, Forcada A, López-Labrador FX. Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective. World J Virol 2013; 2(1): 6-15 [PMID: 24175225 DOI: 10.5501/wjv.v2.i1.6] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
6 Serrano-Villar S, Sobrino-Vegas P, Monge S, Dronda F, Hernando A, Montero M, Viciana P, Clotet B, Pineda JA, Del Amo J, Moreno S; CoRIS. Decreasing prevalence of HCV coinfection in all risk groups for HIV infection between 2004 and 2011 in Spain. J Viral Hepat 2015;22:496-503. [PMID: 25363502 DOI: 10.1111/jvh.12353] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
7 Lee MH, Lu SN, Yuan Y, Yang HI, Jen CL, You SL, Wang LY, L’Italien G, Chen CJ. Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies. PLoS One. 2014;9:e94760. [PMID: 24801353 DOI: 10.1371/journal.pone.0094760] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
8 Levi M, Ahmad A, Bechini A, Boccalini S, Nguyen QV, Veldhuijzen I, Richardus JH, Reintjes R, Bonanni P. Hepatitis B: are at-risk individuals vaccinated if screened and found negative for HBV? Results of an online survey conducted in six EU countries. Vaccine 2014;32:6415-20. [PMID: 25280438 DOI: 10.1016/j.vaccine.2014.09.042] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
9 de Bruijn W, Ibáñez C, Frisk P, Bak Pedersen H, Alkan A, Vella Bonanno P, Brkičić LS, Bucsics A, Dedet G, Eriksen J, Fadare JO, Fürst J, Gallego G, Godói IP, Guerra Júnior AA, Gürsöz H, Jan S, Jones J, Joppi R, Kerman S, Laius O, Madzikwa N, Magnússon E, Maticic M, Markovic-Pekovic V, Massele A, Ogunleye O, O'Leary A, Piessnegger J, Sermet C, Simoens S, Tiroyakgosi C, Truter I, Thyberg M, Tomekova K, Wladysiuk M, Vandoros S, Vural EH, Zara C, Godman B. Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. Front Pharmacol 2016;7:197. [PMID: 27516740 DOI: 10.3389/fphar.2016.00197] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
10 Sanna A, Le Strat Y, Roudot-Thoraval F, Deuffic Burban S, Carrieri P, Delarocque-Astagneau E, Larsen C. Severe liver disease related to chronic hepatitis C virus infection in treatment-naive patients: epidemiological characteristics and associated factors at first expert centre visit, France, 2000 to 2007 and 2010 to 2014. Euro Surveill 2017;22:30582. [PMID: 28797326 DOI: 10.2807/1560-7917.ES.2017.22.30.30582] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Huang DQ, Hoang JK, Leong J, Riveiro-Barciela M, Maeda M, Yang JD, Accarino EV, Thin K, Trinh L, Cheung RC, Roberts LR, Buti M, Schwartz M, Nguyen MH. Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma. Liver Int 2021;41:1922-32. [PMID: 33713386 DOI: 10.1111/liv.14877] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Lee MH, Lu SN, Yuan Y, Yang HI, Jen CL, You SL, Wang LY, L'Italien G, Chen CJ; R.E.V.E.A.L.-HCV Study Group. Development and validation of a clinical scoring system for predicting risk of HCC in asymptomatic individuals seropositive for anti-HCV antibodies. PLoS One 2014;9:e94760. [PMID: 24801353 DOI: 10.1371/journal.pone.0094760] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Catanzaro R, Milazzo M, Arona S, Sapienza C, Vasta D, Arcoria D, Marotta F. Diagnostic accuracy of enhanced liver fibrosis test to assess liver fibrosis in patients with chronic hepatitis C. Hepatobiliary Pancreat Dis Int. 2013;12:500-507. [PMID: 24103280 DOI: 10.1016/s1499-3872(13)60079-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
14 do Amaral AE, Cisilotto J, Creczynski-Pasa TB, de Lucca Schiavon L. Circulating miRNAs in nontumoral liver diseases. Pharmacol Res 2018;128:274-87. [PMID: 29037479 DOI: 10.1016/j.phrs.2017.10.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
15 Owiti JA, Greenhalgh T, Sweeney L, Foster GR, Bhui KS. Illness perceptions and explanatory models of viral hepatitis B & C among immigrants and refugees: a narrative systematic review. BMC Public Health 2015;15:151. [PMID: 25886390 DOI: 10.1186/s12889-015-1476-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
16 Canini L, DebRoy S, Mariño Z, Conway JM, Crespo G, Navasa M, D'Amato M, Ferenci P, Cotler SJ, Forns X, Perelson AS, Dahari H. Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy. Antivir Ther 2015;20:149-55. [PMID: 24912382 DOI: 10.3851/IMP2806] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
17 Myran DT, Morton R, Biggs BA, Veldhuijzen I, Castelli F, Tran A, Staub LP, Agbata E, Rahman P, Pareek M, Noori T, Pottie K. The Effectiveness and Cost-Effectiveness of Screening for and Vaccination Against Hepatitis B Virus among Migrants in the EU/EEA: A Systematic Review. Int J Environ Res Public Health 2018;15:E1898. [PMID: 30200406 DOI: 10.3390/ijerph15091898] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
18 Jang SY, Jang SI, Bae HC, Shin J, Park EC. Sex differences associated with hepatitis B virus surface antigen seropositivity unwareness in hepatitis B virus surface antigen-positive adults: 2007-2012 Korea National Health and Nutrition Examination Survey. J Prev Med Public Health 2015;48:74-83. [PMID: 25857645 DOI: 10.3961/jpmph.14.034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 El Omari K, Iourin O, Kadlec J, Sutton G, Harlos K, Grimes JM, Stuart DI. Unexpected structure for the N-terminal domain of hepatitis C virus envelope glycoprotein E1. Nat Commun. 2014;5:4874. [PMID: 25224686 DOI: 10.1038/ncomms5874] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 7.1] [Reference Citation Analysis]
20 Tsirulnikov K, Abuladze N, Vahi R, Hasnain H, Phillips M, Ryan CM, Atanasov I, Faull KF, Kurtz I, Pushkin A. Aminoacylase 3 binds to and cleaves the N-terminus of the hepatitis C virus core protein. FEBS Lett 2012;586:3799-804. [PMID: 23010594 DOI: 10.1016/j.febslet.2012.09.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
21 Ntziora F, Paraskevis D, Haida C, Manesis E, Papatheodoridis G, Manolakopoulos S, Elefsiniotis I, Karamitros T, Vassilakis A, Hatzakis A. Ultrasensitive amplification refractory mutation system real-time PCR (ARMS RT-PCR) assay for detection of minority hepatitis B virus-resistant strains in the era of personalized medicine. J Clin Microbiol. 2013;51:2893-2900. [PMID: 23804383 DOI: 10.1128/jcm.00936-13] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
22 Fang J, Li W, Tan M, Chen W, Zhang C, Wang W, Xu Q, Guo X. Discontinuation of antiviral prophylaxis increased the risk of hepatitis B virus reactivation in glomerulonephritis patients under immunotherapy: a real-life observation. Int Urol Nephrol 2018;50:1653-60. [PMID: 29644524 DOI: 10.1007/s11255-018-1867-0] [Reference Citation Analysis]
23 Zaltron S, Spinetti A, Biasi L, Baiguera C, Castelli F. Chronic HCV infection: epidemiological and clinical relevance. BMC Infect Dis. 2012;12 Suppl 2:S2. [PMID: 23173556 DOI: 10.1186/1471-2334-12-s2-s2] [Cited by in Crossref: 57] [Cited by in F6Publishing: 26] [Article Influence: 5.7] [Reference Citation Analysis]
24 Coban S, Kekilli M, Köklü S. Approach and management of patients with chronic hepatitis B and C during the course of inflammatory bowel disease. Inflamm Bowel Dis 2014;20:2142-50. [PMID: 25072501 DOI: 10.1097/MIB.0000000000000126] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
25 Hagan LM, Schinazi RF. Best strategies for global HCV eradication. Liver Int. 2013;33 Suppl 1:68-79. [PMID: 23286849 DOI: 10.1111/liv.12063] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 7.2] [Reference Citation Analysis]
26 McGowan CE, Fried MW. Barriers to hepatitis C treatment. Liver Int. 2012;32 Suppl 1:151-156. [PMID: 22212587 DOI: 10.1111/j.1478-3231.2011.02706.x] [Cited by in Crossref: 109] [Cited by in F6Publishing: 104] [Article Influence: 10.9] [Reference Citation Analysis]
27 Voulgaris T, Vlachogiannakos J, Ioannidou P, Papageorgiou MV, Zampeli E, Karagiannakis D, Georgiou A, Papazoglou A, Karamanolis G, Papatheodoridis GV. Adherence to follow-up and treatment recommendations in Greek and immigrant patients with chronic hepatitis B in Greece. Eur J Gastroenterol Hepatol. 2017;29:264-270. [PMID: 27922484 DOI: 10.1097/meg.0000000000000788] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
28 Torres HA, Adachi JA, Roach LR, Smith KM, Mahale PS, Davila M, Raad II. Hepatitis C clinic operated by infectious disease specialists at a comprehensive cancer center: help is on the way. Clin Infect Dis. 2012;54:740-742. [PMID: 22322272 DOI: 10.1093/cid/cir930] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
29 Marrone A, Ciotti M, Rinaldi L, Adinolfi LE, Ghany M. Hepatitis B and C virus infection and risk of haematological malignancies. J Viral Hepat 2020;27:4-12. [PMID: 31325404 DOI: 10.1111/jvh.13183] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Papatheodoridis GV, Sypsa V, Dalekos G, Yurdaydin C, van Boemmel F, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Loglio A, Siakavellas S, Gatselis N, Keskın O, Lehretz M, Savvidou S, de la Revilla J, Hansen BE, Kourikou A, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Berg T, Lampertico P. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. Journal of Hepatology 2018;68:1129-36. [DOI: 10.1016/j.jhep.2018.01.031] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 11.5] [Reference Citation Analysis]
31 Salehi S, Brereton HC, Arno MJ, Darling D, Quaglia A, O'Grady J, Heaton N, Aluvihare VR. Human liver regeneration is characterized by the coordinated expression of distinct microRNA governing cell cycle fate. Am J Transplant. 2013;13:1282-1295. [PMID: 23465054 DOI: 10.1111/ajt.12183] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
32 Bottero J, Boyd A, Lemoine M, Carrat F, Gozlan J, Collignon A, Boo N, Dhotte P, Varsat B, Muller G. Current state of and needs for hepatitis B screening: results of a large screening study in a low-prevalent, metropolitan region. PLoS One. 2014;9:e92266. [PMID: 24663387 DOI: 10.1371/journal.pone.0092266] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
33 Sui G, Li T, Zhang B, Wang R, Hao H, Zhou W. Recent advances on synthesis and biological activities of aurones. Bioorg Med Chem 2021;29:115895. [PMID: 33271454 DOI: 10.1016/j.bmc.2020.115895] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
34 Fitzpatrick T, Pan SW, Tang W, Guo W, Tucker JD. HBV and HCV test uptake and correlates among men who have sex with men in China: a nationwide cross-sectional online survey. Sex Transm Infect 2018;94:502-7. [PMID: 29779005 DOI: 10.1136/sextrans-2018-053549] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
35 Billington S, Ray AS, Salphati L, Xiao G, Chu X, Humphreys WG, Liao M, Lee CA, Mathias A, Hop CECA, Rowbottom C, Evers R, Lai Y, Kelly EJ, Prasad B, Unadkat JD. Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics. Drug Metab Dispos 2018;46:189-96. [PMID: 29138286 DOI: 10.1124/dmd.117.077289] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
36 Bucsics T, Grasl B, Ferlitsch A, Schwabl P, Mandorfer M, Zinober K, Stern R, Chromy D, Scheiner B, Sieghart W, Peck-Radosavljevic M, Trauner M, Reiberger T. Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis. Ultrasound Med Biol 2018;44:2578-86. [PMID: 30241728 DOI: 10.1016/j.ultrasmedbio.2018.07.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
37 Hagan LM, Wolpe PR, Schinazi RF. Treatment as prevention and cure towards global eradication of hepatitis C virus. Trends Microbiol 2013;21:625-33. [PMID: 24238778 DOI: 10.1016/j.tim.2013.09.008] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
38 Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 2014;11:209-19. [PMID: 24247262 DOI: 10.1038/nrgastro.2013.216] [Cited by in Crossref: 155] [Cited by in F6Publishing: 137] [Article Influence: 17.2] [Reference Citation Analysis]
39 Mauss S, Pol S, Buti M, Duffell E, Gore C, Lazarus JV, der Grient HL, Lundgren J, Mozalevskis A, Raben D, Schatz E, Wiktor S, Rockstroh JK; European consensus working group on late presentation for Viral Hepatitis Care. Late presentation of chronic viral hepatitis for medical care: a consensus definition. BMC Med 2017;15:92. [PMID: 28464883 DOI: 10.1186/s12916-017-0856-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
40 Gerlich W, Doerr HW. Therapeutic vaccination in chronic hepatitis B--approaches, problems, and new perspectives. Preface. Med Microbiol Immunol 2015;204:1-4. [PMID: 25550114 DOI: 10.1007/s00430-014-0368-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Caballería L, Pera G, Bernad J, Canut S, Navarro E, Bruguera M. Strategies for the detection of hepatitis C viral infection in the general population. Rev Clin Esp (Barc) 2014;214:242-6. [PMID: 24598246 DOI: 10.1016/j.rce.2014.01.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
42 Marco A, Roget M, Cervantes M, Forné M, Planella R, Miquel M, Ortiz J, Navarro M, Gallego C, Vergara M; In and Out of Prison Study Group. Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and noninmates. J Viral Hepat 2018;25:1280-6. [PMID: 29851225 DOI: 10.1111/jvh.12940] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
43 Robotin M, Patton Y, Kansil M, Penman A, George J. Cost of treating chronic hepatitis B: Comparison of current treatment guidelines. World J Gastroenterol 2012; 18(42): 6106-6113 [PMID: 23155339 DOI: 10.3748/wjg.v18.i42.6106] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
44 Ahmad AA, Falla AM, Duffell E, Noori T, Bechini A, Reintjes R, Veldhuijzen IK. Estimating the scale of chronic hepatitis B virus infection among migrants in EU/EEA countries. BMC Infect Dis 2018;18:34. [PMID: 29325525 DOI: 10.1186/s12879-017-2921-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
45 Bischoff J, Boesecke C, Ingiliz P, Berger F, Simon KG, Lutz T, Schewe CK, Schulze Zur Wiesch J, Hueppe D, Christensen S, Mauss S, Baumgarten A, Rockstroh JK; GECCO study group. Has Increased Rollout of Direct Acting Antiviral Therapy Decreased the Burden of Late Presentation and Advanced Liver Disease in Patients Starting Hepatitis C Virus Therapy in Germany? J Clin Gastroenterol 2020;54:192-9. [PMID: 30789853 DOI: 10.1097/MCG.0000000000001189] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
46 Leblebicioglu H, Arama V, Causse X, Marcellin P, Ozaras R, Postawa-klozinska B, Simon K, Suceveanu AI, Wiese M, Zeuzem S, Klauck I, Morais E, Bjork S, Lescrauwaet B, Kamar D, Zarski JP; The AI463-121 European Longitudinal Chronic Hepatitis B Study Group. Predictors associated with treatment initiation and switch in a real-world chronic hepatitis B population from five European countries. J Viral Hepat 2014;21:662-70. [DOI: 10.1111/jvh.12202] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
47 Lee ACK, Vedio A, Liu EZH, Horsley J, Jesurasa A, Salway S. Determinants of uptake of hepatitis B testing and healthcare access by migrant Chinese in the England: a qualitative study. BMC Public Health 2017;17:747. [PMID: 28950835 DOI: 10.1186/s12889-017-4796-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
48 Canzoni M, Marignani M, Sorgi ML, Begini P, Biondo MI, Caporuscio S, Colonna V, Casa FD, Conigliaro P, Marrese C, Celletti E, Modesto I, Peragallo MS, Laganà B, Picchianti-Diamanti A, Rosa RD, Ferlito C, Salemi S, D'Amelio R, Stroffolini T. Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy. Microorganisms 2020;8:E1792. [PMID: 33207663 DOI: 10.3390/microorganisms8111792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
49 Maticic M, Videcnik Zorman J, Gregorcic S, Schatz E, Lazarus JV. Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries. BMC Infect Dis 2014;14 Suppl 6:S14. [PMID: 25252635 DOI: 10.1186/1471-2334-14-S6-S14] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
50 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 1014] [Article Influence: 153.7] [Reference Citation Analysis]
51 Carballo M, Cody R, Kelly M, Hatzakis A. Migration, Hepatitis B, and Hepatitis C. In: Thomas HC, Lok AS, Locarnini SA, Zuckerman AJ, editors. Viral Hepatitis. Oxford: John Wiley & Sons, Ltd; 2013. pp. 506-14. [DOI: 10.1002/9781118637272.ch37] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
52 Jones L, Bates G, Mccoy E, Beynon C, Mcveigh J, Bellis MA. Effectiveness of interventions to increase hepatitis C testing uptake among high-risk groups: a systematic review. The European Journal of Public Health 2014;24:781-8. [DOI: 10.1093/eurpub/ckt156] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
53 Levi M, Falla A, Taddei C, Ahmad A, Veldhuijzen I, Niccolai G, Bechini A. Referral of newly diagnosed chronic hepatitis B and C patients in six EU countries: results of the HEPscreen Project. Eur J Public Health 2016;26:561-9. [PMID: 27095794 DOI: 10.1093/eurpub/ckw054] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
54 Altinbas A, Baser E, Burkan A, Ertugay E, Kariburyo MF, Baser O. Retrospective analysis of total direct medical costs associated with hepatitis B patients with oral antiviral versus pegylated interferon therapy in Turkey. J Viral Hepat 2014;21:794-801. [DOI: 10.1111/jvh.12206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
55 Ramière C, Roche L, Scholtès C, Iwaz J, Saison J, Ecochard R, André P. Evolution of the incidence of hepatitis B virus infection and immunization rates in a large French cohort born between 1960 and 1994. Clin Microbiol Infect 2016;22:889.e1-7. [PMID: 27451939 DOI: 10.1016/j.cmi.2016.07.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
56 Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58:593-608. [PMID: 23419824 DOI: 10.1016/j.jhep.2012.12.005] [Cited by in Crossref: 744] [Cited by in F6Publishing: 666] [Article Influence: 82.7] [Reference Citation Analysis]
57 García Buey L, González Mateos F, Moreno-otero R. Cirrosis hepática. Medicine - Programa de Formación Médica Continuada Acreditado 2012;11:625-33. [DOI: 10.1016/s0304-5412(12)70359-1] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
58 Hatzakis A, Van Damme P, Alcorn K, Gore C, Benazzouz M, Berkane S, Buti M, Carballo M, Cortes Martins H, Deuffic-Burban S. The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference. J Viral Hepat. 2013;20 Suppl 2:1-20. [PMID: 23827008 DOI: 10.1111/jvh.12120] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.1] [Reference Citation Analysis]
59 Rajasekaran A, Franco RA, Overton ET, McGuire BM, Towns GC, Locke JE, Sawinski DL, Bell EK. Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population. Kidney Int Rep 2021;6:1788-98. [PMID: 34307975 DOI: 10.1016/j.ekir.2021.04.015] [Reference Citation Analysis]
60 Scaglione SJ, Lok AS. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology. 2012;142:1360-1368.e1. [PMID: 22537444 DOI: 10.1053/j.gastro.2012.01.044] [Cited by in Crossref: 92] [Cited by in F6Publishing: 91] [Article Influence: 9.2] [Reference Citation Analysis]
61 Zidan A, Scheuerlein H, Schüle S, Settmacher U, Rauchfuss F. Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in iran and worldwide. Hepat Mon. 2012;12:e6894. [PMID: 23233864 DOI: 10.5812/hepatmon.6894] [Cited by in Crossref: 17] [Cited by in F6Publishing: 31] [Article Influence: 1.7] [Reference Citation Analysis]
62 Papadopoulos N, Manolakopoulos S, Deutsch M, Mela M, Christidou A, Katoglou A, Tzourmakliotis D, Papatheodoridis GV. Frequency and predictors of no treatment in anti-hepatitis C virus-positive patients at tertiary liver centers in Greece. Eur J Gastroenterol Hepatol 2013;25:587-93. [PMID: 23426269 DOI: 10.1097/MEG.0b013e32835cb5c0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
63 Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017;14:122-132. [PMID: 27924080 DOI: 10.1038/nrgastro.2016.176] [Cited by in Crossref: 196] [Cited by in F6Publishing: 191] [Article Influence: 32.7] [Reference Citation Analysis]
64 López-Serrano P, Pérez-Calle JL, Sánchez-Tembleque MD. Hepatitis B and inflammatory bowel disease: Role of antiviral prophylaxis. World J Gastroenterol 2013; 19(9): 1342-1348 [PMID: 23538480 DOI: 10.3748/wjg.v19.i9.1342] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
65 Basnayake SK, Easterbrook PJ. Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature. J Viral Hepat 2016;23:545-59. [PMID: 27028545 DOI: 10.1111/jvh.12519] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
66 Chevaliez S, Poiteau L, Rosa I, Soulier A, Roudot-Thoraval F, Laperche S, Hézode C, Pawlotsky JM. Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care. Clin Microbiol Infect 2016;22:459.e1-6. [PMID: 26806260 DOI: 10.1016/j.cmi.2016.01.009] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
67 Lazarus JV, Sperle I, Spina A, Rockstroh JK. Are the testing needs of key European populations affected by hepatitis B and hepatitis C being addressed? A scoping review of testing studies in Europe. Croat Med J 2016;57:442-56. [PMID: 27815935 DOI: 10.3325/cmj.2016.57.442] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
68 McDonald SA, Innes HA, Hayes PC, Dillon JF, Mills PR, Goldberg DJ, Barclay S, Allen S, Fox R, Fraser A, Kennedy N, Bhattacharyya D, Hutchinson SJ. What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C? J Hepatol 2015;62:262-8. [PMID: 25195556 DOI: 10.1016/j.jhep.2014.08.046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
69 Harris M, Mcdonald B, Rhodes T. Hepatitis C testing for people who inject drugs in the United Kingdom: Why is uptake so low? Drugs: Education, Prevention and Policy 2014;21:333-42. [DOI: 10.3109/09687637.2014.899988] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
70 Samp JC, Perry R, Piercy J, Wood R, Baran RW. Patient health utility, work productivity, and lifestyle impairment in chronic hepatitis C patients in France. Clin Res Hepatol Gastroenterol 2015;39:307-14. [PMID: 25511922 DOI: 10.1016/j.clinre.2014.10.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
71 Duarte G, Williams CJ, Vasconcelos P, Nogueira P. Capacity to report on mortality attributable to chronic hepatitis B and C infections by Member States: An exercise to monitor progress towards viral hepatitis elimination. J Viral Hepat 2018;25:878-82. [PMID: 29479771 DOI: 10.1111/jvh.12882] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Sacco R. Update on entecavir in the management of severe forms of Hepatitis B. Hepat Med 2012;4:39-47. [PMID: 24696620 DOI: 10.2147/HMER.S16136] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
73 Vilarrasa E, Puig L. Psoriasis: Biologic treatment and liver disease. World J Dermatol 2014; 3(4): 76-85 [DOI: 10.5314/wjd.v3.i4.76] [Cited by in CrossRef: 2] [Article Influence: 0.3] [Reference Citation Analysis]
74 Bottero J, Brouard C, Roudot-Thoraval F, Deuffic-Burban S, Hofliger P, Abergel A, Volant J, Dhumeaux D, Yazdanpanah Y; Viral Hepatitis Testing Experts group. 2014 French guidelines for hepatitis B and C screening: a combined targeted and mass testing strategy of chronic viruses namely HBV, HCV and HIV. Liver Int. 2016;36:1442-1449. [PMID: 27043826 DOI: 10.1111/liv.13135] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
75 Glenda Fenili Amorim T, Jönck Staub G, Lazzarotto C, Pacheco Silva A, Manes J, da Graça Ferronato M, Beatriz Cacese Shiozawa M, Luz Narciso-schiavon J, Buzaglo Dantas-correa E, de Lucca Schiavon L. Validation and comparison of simple noninvasive models for the prediction of liver fibrosis in chronic hepatitis C. Annals of Hepatology 2012;11:855-61. [DOI: 10.1016/s1665-2681(19)31410-3] [Cited by in Crossref: 28] [Article Influence: 2.8] [Reference Citation Analysis]
76 daCosta DiBonaventura M, Yuan Y, Wagner JS, L'Italien GJ, Lescrauwaet B, Langley P. The burden of viral hepatitis C in Europe: a propensity analysis of patient outcomes. Eur J Gastroenterol Hepatol 2012;24:869-77. [PMID: 22617367 DOI: 10.1097/MEG.0b013e3283551dee] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
77 Meguellati A, Ahmed-belkacem A, Yi W, Haudecoeur R, Crouillère M, Brillet R, Pawlotsky J, Boumendjel A, Peuchmaur M. B-ring modified aurones as promising allosteric inhibitors of hepatitis C virus RNA-dependent RNA polymerase. European Journal of Medicinal Chemistry 2014;80:579-92. [DOI: 10.1016/j.ejmech.2014.04.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
78 Niederau C. Chronic hepatitis B in 2014: Great therapeutic progress, large diagnostic deficit. World J Gastroenterol 2014; 20(33): 11595-11617 [PMID: 25206267 DOI: 10.3748/wjg.v20.i33.11595] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
79 Papatheodoridis GV, Tsochatzis E, Hardtke S, Wedemeyer H. Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review. Liver Int 2014;34:1452-63. [PMID: 24750532 DOI: 10.1111/liv.12565] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
80 Gane EJ, Rouzier R, Wiercinska-Drapalo A, Larrey DG, Morcos PN, Brennan BJ, Le Pogam S, Nájera I, Petric R, Tran JQ, Kulkarni R, Zhang Y, Smith P, Yetzer ES, Shulman NS. Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders. Antimicrob Agents Chemother 2014;58:1136-45. [PMID: 24295986 DOI: 10.1128/AAC.01515-13] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
81 Stawinska-Witoszynska B, Zysnarska M, Krzywinska-Wiewiorowska M, Wojtyła-Buciorab P, Krzyzaniak A, Wieckowska B. Trends in the Incidence Rates of Chronic Hepatitis B in Poland in the Years 2005 - 2013. Hepat Mon 2016;16:e32692. [PMID: 27799960 DOI: 10.5812/hepatmon.32692] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
82 Poiteau L, Soulier A, Rosa I, Roudot-thoraval F, Hézode C, Pawlotsky J, Chevaliez S. Performance of rapid diagnostic tests for the detection of antibodies to hepatitis C virus in whole blood collected on dried blood spots. J Viral Hepat 2016;23:399-401. [DOI: 10.1111/jvh.12501] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
83 Vandegrift KJ, Critchlow JT, Kapoor A, Friedman DA, Hudson PJ. Peromyscus as a model system for human hepatitis C: An opportunity to advance our understanding of a complex host parasite system. Semin Cell Dev Biol 2017;61:123-30. [PMID: 27498234 DOI: 10.1016/j.semcdb.2016.07.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
84 Mipatrini D, Stefanelli P, Severoni S, Rezza G. Vaccinations in migrants and refugees: a challenge for European health systems. A systematic review of current scientific evidence. Pathog Glob Health 2017;111:59-68. [PMID: 28165878 DOI: 10.1080/20477724.2017.1281374] [Cited by in Crossref: 78] [Cited by in F6Publishing: 61] [Article Influence: 15.6] [Reference Citation Analysis]
85 Wu E, Chen X, Guan Z, Cao C, Rao H, Feng B, Chan M, Fu S, Lin A, Wei L. A comparative study of patients’ knowledge about hepatitis C in the United States and in urban and rural China. Hepatol Int. 2015;9:58-66. [PMID: 25788380 DOI: 10.1007/s12072-014-9559-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
86 Gonzalez-Aldaco K, Roman S, Torres-Valadez R, Ojeda-Granados C, Torres-Reyes LA, Panduro A. Hepatitis C virus clearance and less liver damage in patients with high cholesterol, low-density lipoprotein cholesterol and APOE ε4 allele. World J Gastroenterol 2019; 25(38): 5826-5837 [PMID: 31636475 DOI: 10.3748/wjg.v25.i38.5826] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
87 Bottero J, Boyd A, Gozlan J, Carrat F, Nau J, Pauti MD, Rougier H, Girard PM, Lacombe K. Simultaneous Human Immunodeficiency Virus-Hepatitis B-Hepatitis C Point-of-Care Tests Improve Outcomes in Linkage-to-Care: Results of a Randomized Control Trial in Persons Without Healthcare Coverage. Open Forum Infect Dis. 2015;2:ofv162. [PMID: 26668814 DOI: 10.1093/ofid/ofv162] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
88 Cordero-Coma M, Salazar-Méndez R, Yilmaz T. Treatment of severe non-infectious uveitis in high-risk conditions (Part 2): systemic infections; management and safety issues. Expert Opin Drug Saf 2015;14:1353-71. [PMID: 26118392 DOI: 10.1517/14740338.2015.1061992] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
89 Rossi C, Schwartzman K, Oxlade O, Klein MB, Greenaway C. Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis. PLoS One. 2013;8:e78548. [PMID: 24205255 DOI: 10.1371/journal.pone.0078548] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
90 Bottero J, Boyd A, Gozlan J, Carrat F, Lemoine M, Rougier H, Varsat B, Boo N, Charlois-Ou C, Collignon A. Effectiveness of hepatitis B rapid tests toward linkage-to-care: results of a randomized, multicenter study. Eur J Gastroenterol Hepatol. 2016;28:633-639. [PMID: 26954517 DOI: 10.1097/meg.0000000000000620] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
91 Nau AL, Fayad L, Lazzarotto C, Shiozawa MB, Dantas-Corrêa EB, Schiavon Lde L, Narciso-Schiavon JL. Prevalence and clinical features of celiac disease in patients with hepatitis B virus infection in Southern Brazil. Rev Soc Bras Med Trop 2013;46:397-402. [PMID: 23982094 DOI: 10.1590/0037-8682-0093-2013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
92 GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:245-266. [PMID: 31981519 DOI: 10.1016/s2468-1253(19)30349-8] [Cited by in Crossref: 167] [Cited by in F6Publishing: 75] [Article Influence: 83.5] [Reference Citation Analysis]
93 Axiaris G, Zampeli E, Michopoulos S, Bamias G. Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment. World J Gastroenterol 2021; 27(25): 3762-3779 [PMID: 34321842 DOI: 10.3748/wjg.v27.i25.3762] [Reference Citation Analysis]
94 Baser O, Altinbas A, Baser E, Kariburyo MF. Economic Impact and Complications of Treated and Untreated Hepatitis C Virus Patients in Turkey. Value Health Reg Issues 2015;7:42-8. [PMID: 29698151 DOI: 10.1016/j.vhri.2015.08.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
95 Ozaras R, Corti G, Ruta S, Lacombe K, Mondelli M, Irwing W, Puoti M, Khalighi A, Santos M, Harxhi A, Lazarevic I, Soriano V, Gervain J, Leblebicioglu H, Salmon D, Arends J. Differences in the availability of diagnostics and treatment modalities for chronic hepatitis B across Europe. Clinical Microbiology and Infection 2015;21:1027-32. [DOI: 10.1016/j.cmi.2015.07.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
96 Hotho DM, Kreefft K, Groothuismink ZM, Janssen HL, de Knegt RJ, Boonstra A. Natural killer cell activity and function in chronic HCV-infected patients during peg interferon and ribavirin: early effects of active substance use. Antiviral Res 2013;97:347-55. [PMID: 23291200 DOI: 10.1016/j.antiviral.2012.12.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
97 Krämer C, Jaspers N, Nierhoff D, Kuhr K, Bowe A, Goeser T, Michels G. Acoustic structure quantification ultrasound software proves imprecise in assessing liver fibrosis or cirrhosis in parenchymal liver diseases. Ultrasound Med Biol 2014;40:2811-8. [PMID: 25308947 DOI: 10.1016/j.ultrasmedbio.2014.07.020] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
98 Diaz-Mitoma F, Popovic V, Spaans JN. Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac®, compared with Engerix-B® in healthy Asian adults: A phase 3 randomized clinical trial. Vaccine 2021;39:3892-9. [PMID: 34116873 DOI: 10.1016/j.vaccine.2021.05.067] [Reference Citation Analysis]
99 Hadinedoushan H, Salmanroghani H, Amirbaigy MK, Akhondi-Meybodi M. Hepatitis C virus genotypes and association with viral load in yazd, central province of iran. Hepat Mon 2014;14:e11705. [PMID: 24693314 DOI: 10.5812/hepatmon.11705] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
100 Alanko Blomé M, Björkman P, Molnegren V, Höglund P, Widell A. Hepatitis C viremia patterns in incident hepatitis C infection and one year later in 150 prospectively tested persons who inject drugs. PLoS One 2014;9:e97022. [PMID: 24830647 DOI: 10.1371/journal.pone.0097022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
101 Vermunt J, Fraser M, Herbison P, Wiles A, Schlup M, Schultz M. Prevalence and knowledge of hepatitis C in a middle-aged population, Dunedin, New Zealand. World J Gastroenterol 2015; 21(35): 10224-10233 [PMID: 26401088 DOI: 10.3748/wjg.v21.i35.10224] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
102 Raven S, Urbanus A, de Gee A, Hoebe C, van Steenbergen J. Predictors of hepatitis B vaccination completion among people who use drugs participating in a national program of targeted vaccination. Vaccine 2018;36:5282-7. [PMID: 30061025 DOI: 10.1016/j.vaccine.2018.07.045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
103 Vassilopoulos D, Calabrese LH. Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol 2012;8:348-57. [DOI: 10.1038/nrrheum.2012.63] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
104 Fitzsimons D, Hendrickx G, Lernout T, Badur S, Vorsters A, Van Damme P. Incentives and barriers regarding immunization against influenza and hepatitis of health care workers. Vaccine 2014;32:4849-54. [DOI: 10.1016/j.vaccine.2014.06.072] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
105 Moldoveanu I, Stefan-van staden R, Frederick van staden J. Chitosan Based Diamond Paste Stochastic Microsensors Modified with Gold Nanoparticles Detect Hepatitis C Virus Core Antigen. Electroanalysis 2015;27:1842-6. [DOI: 10.1002/elan.201500081] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
106 Pradat P, Virlogeux V, Trépo E. Epidemiology and Elimination of HCV-Related Liver Disease. Viruses 2018;10:E545. [PMID: 30301201 DOI: 10.3390/v10100545] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
107 Atlaw D, Sahiledengle B, Tariku Z. Hepatitis B and C virus infection among healthcare workers in Africa: a systematic review and meta-analysis. Environ Health Prev Med 2021;26:61. [PMID: 34078258 DOI: 10.1186/s12199-021-00983-9] [Reference Citation Analysis]
108 Deuffic-Burban S, Yazdanpanah Y. It is time to change the paradigm for hepatitis C virus testing. Clin Infect Dis 2012;54:1272-4. [PMID: 22419684 DOI: 10.1093/cid/cis047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
109 Sacks-Davis R, VAN Gemert C, Bergeri I, Stoove M, Hellard M. Identifying newly acquired cases of hepatitis C using surveillance: a literature review. Epidemiol Infect 2012;140:1925-34. [PMID: 22651915 DOI: 10.1017/S0950268812001033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
110 Garbuglia AR, Monachetti A, Galli C, Sabatini R, Ferreri ML, Capobianchi MR, Bagnarelli P. HCV core antigen and HCV-RNA in HIV/HCV co-infected patients with different HCV genotypes. BMC Infect Dis. 2014;14:222. [PMID: 24758157 DOI: 10.1186/1471-2334-14-222] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
111 Gigi E, Sinakos E, Sykja A, Androulakis G, Tanis C, Stayridou V, Tsirogianni E, Zouridakis K, Bellou AL, Orfanou E. Epidemiology, clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug users. J Addict Med. 2013;7:52-57. [PMID: 23340710 DOI: 10.1097/adm.0b013e318279756f] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
112 Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex 2021:S0375-0906(21)00061-6. [PMID: 34384668 DOI: 10.1016/j.rgmx.2021.04.002] [Reference Citation Analysis]
113 Tujios SR, Lee WM. New advances in chronic hepatitis B. Curr Opin Gastroenterol. 2012;28:193-197. [PMID: 22450894 DOI: 10.1097/mog.0b013e32835297ef] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
114 Boyd A, Bottero J, Carrat F, Gozlan J, Rougier H, Girard PM, Lacombe K. Testing for hepatitis B virus alone does not increase vaccine coverage in non-immunized persons. World J Gastroenterol 2017; 23(38): 7037-7046 [PMID: 29097876 DOI: 10.3748/wjg.v23.i38.7037] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
115 La Torre G, Mannocci A, Saulle R, Colamesta V, Meggiolaro A, Mipatrini D, Sinopoli A. Economic evaluation of HBV vaccination: A systematic review of recent publications (2000-2013). Hum Vaccin Immunother 2016;12:2299-311. [PMID: 27105443 DOI: 10.1080/21645515.2016.1166328] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
116 Roux P, Sagaon-Teyssier L, Lions C, Fugon L, Verger P, Carrieri MP. HCV seropositivity in inmates and in the general population: an averaging approach to establish priority prevention interventions. BMJ Open. 2014;4:e005694. [PMID: 25331969 DOI: 10.1136/bmjopen-2014-005694] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
117 Robotin MC, George J. Community-based hepatitis B screening: what works? Hepatol Int 2014;8:478-92. [PMID: 25298848 DOI: 10.1007/s12072-014-9562-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
118 Locarnini S, Hatzakis A, Chen DS, Lok A. Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. J Hepatol. 2015;62:S76-S86. [PMID: 25920093 DOI: 10.1016/j.jhep.2015.01.018] [Cited by in Crossref: 120] [Cited by in F6Publishing: 117] [Article Influence: 20.0] [Reference Citation Analysis]
119 Gergely A, Bechet S, Goujon C, Benabdelmoumen G, Consigny PH. Hepatitis B screening in travelers: a retrospective analysis. Travel Med Infect Dis 2014;12:707-12. [PMID: 25086491 DOI: 10.1016/j.tmaid.2014.07.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
120 Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, Murray CJ, Naghavi M. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med. 2014;12:145. [PMID: 25242656 DOI: 10.1186/s12916-014-0145-y] [Cited by in Crossref: 467] [Cited by in F6Publishing: 427] [Article Influence: 58.4] [Reference Citation Analysis]
121 Di Poto C, He S, Varghese RS, Zhao Y, Ferrarini A, Su S, Karabala A, Redi M, Mamo H, Rangnekar AS, Fishbein TM, Kroemer AH, Tadesse MG, Roy R, Sherif ZA, Kumar D, Ressom HW. Identification of race-associated metabolite biomarkers for hepatocellular carcinoma in patients with liver cirrhosis and hepatitis C virus infection. PLoS One 2018;13:e0192748. [PMID: 29538406 DOI: 10.1371/journal.pone.0192748] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
122 Papatheodoridis G, Sypsa V, Kantzanou M, Nikolakopoulos I, Hatzakis A. Estimating the treatment cascade of chronic hepatitis B and C in Greece using a telephone survey. J Viral Hepat. 2015;22:409-415. [PMID: 25209157 DOI: 10.1111/jvh.12314] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
123 Lazarus JV, Mozalevskis A, Safreed-Harmon K, Eramova I. Strengthening hepatitis B and C surveillance in Europe: results from the two global hepatitis policy surveys (2013 and 2014). Hepatol Med Policy 2016;1:3. [PMID: 30288307 DOI: 10.1186/s41124-016-0009-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
124 McPherson S, Valappil M, Moses SE, Eltringham G, Miller C, Baxter K, Chan A, Shafiq K, Saeed A, Qureshi R. Targeted case finding for hepatitis B using dry blood spot testing in the British-Chinese and South Asian populations of the North-East of England. J Viral Hepat. 2013;20:638-644. [PMID: 23910648 DOI: 10.1111/jvh.12084] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
125 Jones L, Atkinson A, Bates G, McCoy E, Porcellato L, Beynon C, McVeigh J, Bellis MA. Views and experiences of hepatitis C testing and diagnosis among people who inject drugs: systematic review of qualitative research. Int J Drug Policy 2014;25:204-11. [PMID: 24332457 DOI: 10.1016/j.drugpo.2013.11.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
126 Drositis I, Bertsias A, Lionis C, Kouroumalis E. Epidemiology and molecular analysis of hepatitis A, B and C in a semi-urban and rural area of Crete. Eur J Intern Med. 2013;24:839-845. [PMID: 23988264 DOI: 10.1016/j.ejim.2013.08.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
127 Chinnaratha MA, Jeffrey GP, Macquillan G, Rossi E, de Boer BW, Speers DJ, Adams LA. Prediction of morbidity and mortality in patients with chronic hepatitis C by non-invasive liver fibrosis models. Liver Int 2014;34:720-7. [DOI: 10.1111/liv.12306] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
128 Karayiannis P. Direct acting antivirals for the treatment of chronic viral hepatitis. Scientifica (Cairo) 2012;2012:478631. [PMID: 24278700 DOI: 10.6064/2012/478631] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
129 Antonucci G, Mazzotta F, Puoti M, Angeletti C, Girardi E, Santantonio T, Ambu S, Gaeta GB, Colucci M, Angarano G, Marino N, Rinaldi R, Bellissima P, Armignacco O, Carosi G, Sagnelli E; Coorte Epatiti B SIMIT (COESI-B) Group. Factors associated with access to antiviral treatment in a multicentre cross-sectional study of patients with chronic hepatitis B in Italy. J Viral Hepat 2012;19:881-9. [PMID: 23121367 DOI: 10.1111/j.1365-2893.2012.01615.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
130 Lugoboni F, Pavarin RM, Resentera C, Gambini D. Let It "B"? The role of Hepatitis B universal vaccination among italian problematic drug users. Int J Environ Res Public Health 2015;12:3979-92. [PMID: 25872013 DOI: 10.3390/ijerph120403979] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
131 Pérez-Matute P, Oteo JA. Is it enough to eliminate hepatitis C virus to reverse the damage caused by the infection? World J Clin Infect Dis 2017; 7(1): 1-5 [DOI: 10.5495/wjcid.v7.i1.1] [Reference Citation Analysis]
132 Chen DS, Locarnini S, Wait S, Bae SH, Chen PJ, Fung JY, Kim HS, Lu SN, Sung J, Tanaka J, Wakita T, Ward J, Wallace J; CEVHAP North Asia Workshop on Viral Hepatitis. CEVHAP North Asia Workshop on Viral Hepatitis. Report from a Viral Hepatitis Policy Forum on implementing the WHO Framework for Global Action on viral hepatitis in North Asia. J Hepatol. 2013;59:1073-1080. [PMID: 23850942 DOI: 10.1016/j.jhep.2013.06.029] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
133 Saleha S, Kamal A, Ullah F, Khan N, Mahmood A, Khan S. Prevalence of hepatitis C virus genotypes in district bannu, khyber pakhtunkhwa, pakistan. Hepat Res Treat. 2014;2014:165826. [PMID: 25093120 DOI: 10.1155/2014/165826] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
134 Afridi SQ, Zahid MN, Shabbir MZ, Hussain Z, Mukhtar N, Tipu MY, Akhtar F, Yaqub T. Prevalence of HCV genotypes in district Mardan. Virol J. 2013;10:90. [PMID: 23514695 DOI: 10.1186/1743-422x-10-90] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
135 Boyd A, Gozlan J, Carrat F, Rougier H, Girard PM, Lacombe K, Bottero J. Self-reported patient history to assess hepatitis B virus serological status during a large screening campaign. Epidemiol Infect 2018;147:e16. [PMID: 30264683 DOI: 10.1017/S0950268818002650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
136 Scalone L, Fagiuoli S, Ciampichini R, Gardini I, Bruno R, Pasulo L, Lucà MG, Fusco F, Gaeta L, Del Prete A, Cesana G, Mantovani LG. The societal burden of chronic liver diseases: results from the COME study. BMJ Open Gastroenterol 2015;2:e000025. [PMID: 26462277 DOI: 10.1136/bmjgast-2014-000025] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
137 Soulier A, Poiteau L, Rosa I, Hézode C, Roudot-Thoraval F, Pawlotsky JM, Chevaliez S. Dried Blood Spots: A Tool to Ensure Broad Access to Hepatitis C Screening, Diagnosis, and Treatment Monitoring. J Infect Dis. 2016;213:1087-1095. [PMID: 26333945 DOI: 10.1093/infdis/jiv423] [Cited by in Crossref: 76] [Cited by in F6Publishing: 73] [Article Influence: 10.9] [Reference Citation Analysis]
138 Castelain S, Descamps V, Brochot E, Helle F, Duverlie G, Nguyen-Khac E, François C. High association of T1858-G1896 precore mutations with impaired base pairing and high hepatitis B virus DNA levels in HBeAg-negative chronically infected patients. Arch Virol 2017;162:1913-20. [PMID: 28289975 DOI: 10.1007/s00705-017-3312-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
139 Meguellati A, Ahmed-Belkacem A, Nurisso A, Yi W, Brillet R, Berqouch N, Chavoutier L, Fortuné A, Pawlotsky JM, Boumendjel A, Peuchmaur M. New pseudodimeric aurones as palm pocket inhibitors of Hepatitis C virus RNA-dependent RNA polymerase. Eur J Med Chem 2016;115:217-29. [PMID: 27017550 DOI: 10.1016/j.ejmech.2016.03.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
140 Schaefer EA, Chung RT. Anti−Hepatitis C Virus Drugs in Development. Gastroenterology 2012;142:1340-1350.e1. [DOI: 10.1053/j.gastro.2012.02.015] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 6.3] [Reference Citation Analysis]
141 Razin M, Abdel-Ghaffar AB, Hamdy GM, Abd-Elshafy DN, Kamel S, Bahgat MM, Maghraby AS. TLR3\TLR7 as Differentially Expressed Markers Among Viral, Nonviral, and Autoimmune Diseases in Egyptian Patients. Viral Immunol 2021. [PMID: 34342515 DOI: 10.1089/vim.2021.0006] [Reference Citation Analysis]
142 Roesch-Dietlen F, González-Santes M, Sánchez-Maza YJ, Díaz-Roesch F, Cano-Contreras AD, Amieva-Balmori M, García-Zermeño KR, Salgado-Vergara L, Remes-Troche JM, Ortigoza-Gutiérrez S. Influence of socioeconomic and cultural factors in the etiology of cirrhosis of the liver. Rev Gastroenterol Mex (Engl Ed) 2021;86:28-35. [PMID: 32345507 DOI: 10.1016/j.rgmx.2020.01.002] [Reference Citation Analysis]
143 Liu X, Chen Y, Wang Y, Dong X, Wang J, Tang J, Sundquist K, Sundquist J, Ji J. Cancer risk in patients with hepatitis C virus infection: a population-based study in Sweden. Cancer Med 2017;6:1135-40. [PMID: 28374973 DOI: 10.1002/cam4.988] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
144 Papatheodoridis G, Hatzakis A. Public health issues of hepatitis C virus infection. Best Practice & Research Clinical Gastroenterology 2012;26:371-80. [DOI: 10.1016/j.bpg.2012.09.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
145 Karacaer Z, Okur G, Cermik H, Altun D. Is there an influence of hepatic steatosis on fibrosis and necroinflammation in young patients with chronic viral hepatitis B? Postgrad Med 2016;128:697-700. [PMID: 27499150 DOI: 10.1080/00325481.2016.1221733] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
146 Doyle JS, Sacks-davis R, Hellard ME. Acute Hepatitis C Infection: New Approaches to Surveillance, Treatment and Prevention. Curr Hepatitis Rep 2012;11:221-30. [DOI: 10.1007/s11901-012-0143-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
147 Bechini A, Falla A, Ahmad A, Veldhuijzen I, Boccalini S, Porchia B, Levi M. Identification of hepatitis B and C screening and patient management guidelines and availability of training for chronic viral hepatitis among health professionals in six European countries: results of a semi-quantitative survey. BMC Infect Dis 2015;15:353. [PMID: 26286525 DOI: 10.1186/s12879-015-1104-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
148 Duffell EF, Hedrich D, Mardh O, Mozalevskis A. Towards elimination of hepatitis B and C in European Union and European Economic Area countries: monitoring the World Health Organization's global health sector strategy core indicators and scaling up key interventions. Euro Surveill 2017;22:30476. [PMID: 28277217 DOI: 10.2807/1560-7917.ES.2017.22.9.30476] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
149 Marascio N, Liberto M, Barreca G, Zicca E, Quirino A, Lamberti A, Bianco G, Matera G, Surace L, Berardelli G. Update on epidemiology of HCV in Italy: focus on the Calabria Region. BMC Infect Dis. 2014;14 Suppl 5:S2. [PMID: 25236184 DOI: 10.1186/1471-2334-14-s5-s2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
150 Lopez-Delgado JC, Ballus J, Esteve F, Betancur-Zambrano NL, Corral-Velez V, Mañez R, Betbese AJ, Roncal JA, Javierre C. Outcomes of abdominal surgery in patients with liver cirrhosis. World J Gastroenterol 2016; 22(9): 2657-2667 [PMID: 26973406 DOI: 10.3748/wjg.v22.i9.2657] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
151 Vietri J, Prajapati G, El Khoury AC. The burden of hepatitis C in Europe from the patients’ perspective: a survey in 5 countries. BMC Gastroenterol. 2013;13:16. [PMID: 23324473 DOI: 10.1186/1471-230x-13-16] [Cited by in Crossref: 49] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
152 Parry S, Bundle N, Ullah S, Foster GR, Ahmad K, Tong CYW, Balasegaram S, Orkin C. Implementing routine blood-borne virus testing for HCV, HBV and HIV at a London Emergency Department - uncovering the iceberg? Epidemiol Infect 2018;146:1026-35. [PMID: 29661260 DOI: 10.1017/S0950268818000870] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
153 Gountas I, Sypsa V, Papatheodoridis G, Souliotis G, Razavi H, Hatzakis A. Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece. J Gastroenterol Hepatol. 2017;32:466-472. [PMID: 27403912 DOI: 10.1111/jgh.13485] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
154 Khan N, Akmal M, Hayat M, Umar M, Ullah A, Ahmed I, Rahim K, Ali S, Bahadar S, Saleha S. Geographic distribution of hepatitis C virus genotypes in pakistan. Hepat Mon. 2014;14:e20299. [PMID: 25477975 DOI: 10.5812/hepatmon.20299] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
155 Ahn HR, Cho SB, Chung IJ, Kweon SS. Socioeconomic differences in self- and family awareness of viral hepatitis status among carriers of hepatitis B or C in rural Korea. Am J Infect Control 2018;46:328-32. [PMID: 29103635 DOI: 10.1016/j.ajic.2017.09.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
156 Veldhuijzen IK, Wolter R, Rijckborst V, Mostert M, Voeten HA, Cheung Y, Boucher CA, Reijnders JG, de Zwart O, Janssen HL. Identification and treatment of chronic hepatitis B in Chinese migrants: results of a project offering on-site testing in Rotterdam, The Netherlands. J Hepatol. 2012;57:1171-1176. [PMID: 22885717 DOI: 10.1016/j.jhep.2012.07.036] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]